Lesson 3 - Diagnosing Celiac Disease
3.5 Diagnostic algorithm
Below you can find the diagnostic algorithms (fig. 16) to diagnose CeD in children with symptoms or signs suggestive of celiac disease or in at-risk groups (Husby et al. 2020).
The updated guidelines and the algorithm for diagnosing CeD in children and adolescents were published in 2020. According to these guidelines, the no-biopsy approach to diagnose CeD can be applied in both symptomatic and asymptomatic children with TGA-IgA of at least 10-times the upper limit of normal. However, the decision whether or not to perform diagnostic duodenal biopsies should be made during a shared decision making process together with the parent(s) and, if appropriate, with the child. As explained previously, a positive EMA-IgA test result form a 2nd blood withdrawal is necessary to confirm the diagnosis of CeD.
This algorithm explains the diagnostic approach in children at initial stage and in the specialist care. It also provides instructions for diagnosing CeD in children with normal IgA, with low or absent IgA and the instructions for duodenal biopsies.
It is recommended to perform total IgA and TGA-IgA as initial screening in children, regardless of age, with clinical suspicion of CeD or belonging to a CeD risk group.
If the initial TGA-IgA test is positive, further investigations are always needed to confirm the diagnosis and the child should be referred to a paediatric gastroenterologist (or paediatrician skilled in CeD diagnosis).
If the initial TGA-IgA test is negative:
- total IgA concentration should be reviewed and if low, paediatric gastroenterologist should be consulted
- the risk of false negative serology should be considered and if any, again paediatric gastroenterologist should be consulted
At specialist care, the results of the initial TGA-IgA antibodies and total IgA should be reviewed and diagnostic pathways discussed with the family.
In children with TGA ≥10X ULN, and parents/patient agreement to the no-biopsy approach, the CeD diagnosis should be confirmed by a positive EMA-IgA test in a second blood sample.
In patients with absent or low total IgA, an IgG-based test (DGP, EMA or TGA) should be performed. In IgA deficient cases biopsies should not be omitted.
If there is a risk for false negative serology, HLA-DQ2/DQ8 determination can be considered. If negative, CD is unlikely.